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Abstract
Background: Pyoderma gangrenosum (PG) is a rare inflammatory skin disorder characterised by painful and rapidly
progressing skin ulceration. PG can be extremely difficult to treat and patients often require systemic
immunosuppression. Recurrent lesions of PG are common, but the relative rarity of this condition means that there
is a lack of published evidence regarding its treatment. A systematic review published in 2005 found no
randomised controlled trials (RCTs) relating to the treatment of PG. Since this time, one small RCT has been
published comparing infliximab to placebo, but none of the commonly used systemic treatments for PG have been
formally assessed. The UK Dermatology Clinical Trials Network’s STOP GAP Trial has been designed to address this
lack of trial evidence.
Methods: The objective is to assess whether oral ciclosporin is more effective than oral prednisolone for the
treatment of PG. The trial design is a two-arm, observer-blind, parallel-group, randomised controlled trial comparing
ciclosporin (4 mg/kg/day) to prednisolone (0.75 mg/kg/day). A total of 140 participants are to be recruited over a
period of 4 years, from up to 50 hospitals in the UK and Eire. Primary outcome of velocity of healing at 6 weeks is
assessed blinded to treatment allocation (using digital images of the ulcers). Secondary outcomes include: (i) time
to healing; (ii) global assessment of improvement; (iii) PG inflammation assessment scale score; (iv) self-reported
pain; (v) health-related quality of life; (vi) time to recurrence; (vii) treatment failures; (viii) adverse reactions to study
medications; and (ix) cost effectiveness/utility. Patients with a clinical diagnosis of PG (excluding granulomatous PG);
measurable ulceration (that is, not pustular PG); and patients aged over 18 years old who are able to give informed
consent are included in the trial. Randomisation is by computer generated code using permuted blocks of
randomly varying size, stratified by lesion size, and presence or absence of underlying systemic disease (for example,
rheumatoid arthritis).
Patients who require topical therapy are asked to enter a parallel observational study (case series). If topical therapy
fails and systemic therapy is required, participants are then considered for inclusion in the randomised trial.
Trial registration: Current controlled trials: ISRCTN35898459. Eudract No.2008-008291-14.
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Background
Pyoderma gangrenosum (PG) is a rare inflammatory
dermatosis characterised by painful and rapidly progres-
sive skin ulceration [1,2]. It most commonly affects the
lower limbs, but can affect any other site including the
peristomal area. It can be seen in association with a
number of conditions including inflammatory bowel dis-
ease, rheumatoid arthritis, haematological disorders and
malignancies [3-5]. It is a disease that causes consider-
able morbidity to patients, who often have a poor quality
of life and high need for healthcare resources. Many
patients require hospitalization for initial control, and
regular changes of dressings by community care teams.
PG can be extremely difficult to treat and recurrent
lesions are common [5]. There is a lack of published evi-
dence regarding its treatment, largely because large-scale
RCTs are difficult to conduct in a rare condition such as
this. A systematic review in 2005 recommended the use
of prednisolone, ciclosporin or high-dose intravenous
steroids for large lesions; or potent topical steroids,
tacrolimus or intralesional steroid injection for small
lesions [6]. Other reviews have suggested a similar step-
wise approach [7]. However, these recommendations
were based on case series alone as no RCTs of these
most commonly used treatments were identified and
clinical guidelines are currently lacking. There has been
one randomised controlled trial demonstrating superior-
ity of infliximab over placebo [8], but such a potent drug
would rarely be used as first line treatment. Many of the
commonly used treatments are associated with unpleas-
ant and potentially serious side effects, making their for-
mal evaluation a matter of urgency. These treatments are
currently being used for patients with PG without rigor-
ous testing, or understanding of their relative efficacy,
cost and side-effect profile.
In order to begin to address this lack of evidence, the
first randomised controlled trial of systemic treatments
for pyoderma gangrenosum is being carried out. The
‘Study of Treatments fOr Pyoderma GAngrenosum
Patients’ (STOP GAP) will compare the two most com-
monly used systemic treatments: prednisolone and
ciclosporin. The trial was granted ethics approval by the
Northern and Yorkshire research ethics committee
(MREC reference: 09/H0903/5), and all participants gave
written informed consent. This paper is based on a sum-
mary of the current protocol (version 4.0, 30 August
2011. Further details are available on the STOP GAP
Trial website at http://www.stopgaptrial.co.uk) [9].
Methods
Design
STOP GAP is a multicentre, parallel group, observer-
blind, randomised controlled trial (Figure 1). This is a
superiority trial, with prednisolone as the control inter-
vention. The decision to power the STOP GAP trial on
the basis of superiority was made as (i) ciclosporin is
considerably more expensive than prednisolone (which
means that it would need to be considerably better than
Figure 1 Flow chart of trial recruitment.
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prednisolone to warrant a change in clinical practice); (ii)
case series and clinical experience give the impression
that ciclosporin may gain control more quickly, and have
a side-effect profile that is more suitable for long-term
therapy; and (iii) pragmatically, for a rare condition such
as PG, this was felt to be the best approach as an equiva-
lence trial would require a much larger trial that could
only be delivered internationally, which was beyond the
scope of our funding.
The study aims to recruit 140 patients with PG over a
4-year period. Participants are randomised using a ratio of
1:1 to receive either oral prednisolone (0.75 mg/kg/day)
or oral ciclosporin (4 mg/kg/day). Patients who initially
require topical therapy are asked to enter a parallel obser-
vational study, the purpose of which is to provide an esti-
mate of treatment response to topical therapy in a well
defined prospective case series, and also to enhance re-
cruitment by allowing those who fail on topical therapy to
enter the main study (Figure 1).
Follow-up is continued until the lesion has healed, or
for a maximum of 6 months (whichever is sooner).
Objectives
The primary objective for this trial is to assess the speed
of response to treatment for the compared treatments.
Secondary objectives are to assess overall treatment re-
sponse (especially time to healing), safety, and cost ef-
fectiveness of the compared treatments.
Participants
Patients aged over 18 years with a clinical diagnosis of
PG (as diagnosed by the recruiting dermatologist) can be
enrolled into the study. There must be measurable ulcer-
ation (that is, not pustular PG) for the patient to be
included. In keeping with the pragmatic nature of the
study, a positive skin biopsy is not required for diagnosis
since histology is rarely diagnostic, but should be per-
formed as part of normal care in cases of diagnostic un-
certainty in order to exclude alternative diagnoses. For
cases where there is doubt over the clinical diagnosis, an
expert panel is available to provide assistance in confirm-
ing or refuting the diagnosis.
Patients are not eligible for the study if they: (i) have
granulomatous PG (which is very rare, and may respond
differently to treatment); (ii) have received oral prednisol-
one, oral ciclosporin or intravenous immunoglobulins
within 1 month prior to randomisation; or (iii) are already
participating in another clinical trial. In addition patients
are not eligible for the RCT arm of the study if they (i) are
pregnant, lactating or at risk of pregnancy; (ii) have known
hypersensitivity to either of the study drugs; (iii) have a bi-
opsy result that is consistent with a diagnosis other than
PG; (iv) have clinically significant renal impairment that
would result in the investigator not normally treating with
either study drug; (v) have any pretreatment investigations,
the results of which would prompt the investigator not to
use either study drug; (vi) have any malignant of premalig-
nant disease where treatments might interfere with on-
going therapy or might cause harm; (vii) have any
concurrent medical condition which would preclude treat-
ment with either of the study medications; (viii) adminis-
tration of a live vaccine within 2 weeks prior to
randomisation; or (ix) are currently taking Rosuvastatin
(Crestor) for hypercholesterolaemia, since this is contrain-
dicated in patients taking ciclosporin.
Interventions
Participants are randomised to receive either oral prednis-
olone 0.75 mg/kg/day or ciclosporin (Neoral) 4 mg/kg/day
(in two divided doses), up to a ceiling dose of 75 mg/day
prednisolone and 400 mg/day ciclosporin. The dose of
study drug can be adjusted (up or down) by the investiga-
tor according to response after the week 2 visit. If possible
the dose of study drug should not be altered for the first
2 weeks of the study.
The use of a double dummy design was not felt to be ap-
propriate for this study as the side effect profile, monitor-
ing requirements and dosing regimen for the compared
drugs is very different, making such a design both costly
and possibly ineffective. As a result the trial team opted to
ensure blinded outcome assessment of the primary out-
come (using digital images) and secure allocation conceal-
ment. Participants are prescribed study medication from
standard pharmacy supplies at each recruiting hospital.
Participants of the RCT should not use any topical ther-
apy (for example, corticosteroids or calcineurin inhibitors)
after randomisation. If topical therapy has been prescribed
while the participant is waiting to enter the study it should
be stopped when the participant enters the RCT. All other
concomitant medications should continue as per normal
care. The use of live vaccines is not permitted during the
intervention phase of the trial and clinicians will be
advised not to start Rosuvastatin (Crestor) on any patients
receiving ciclosporin as it is contraindicated. Participants
are asked to assess how well they adhered to study drug at
week 6 and at 6 months (or time of healing).
Participants in the observational arm of the study receive
whichever topical therapy is prescribed as per normal care
at the recruiting hospital (this is most likely to be clobeta-
sol propionate (Dermovate) or tacrolimus (Protopic 0.1%
or 0.03%) as there is reasonable evidence to support the
use of both of these treatments [10,11].
Randomisation and blinding (masking)
The randomisation schedule has been created by the
Nottingham Clinical Trials Unit data manager using the
ralloc Strata (College Station, TX, USA) add-on. Partici-
pants are randomised to treatment allocation using a
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computer-generated pseudorandom list using permuted
blocks of randomly varying size between 2 and 6. Random-
isation is stratified by lesion size (≥20 cm2 vs lesions
<20 cm2) and presence or absence of underlying systemic
disease. The randomisation schedule will be concealed
until interventions are all assigned and recruitment, data
collection, data cleaning and analysis are complete.
This is an observer-blind study. The primary outcome
(velocity of healing) is assessed on the basis of digital
images of the target lesion in order to protect against de-
tection bias. The digital images will be assessed by two
assessors who are blinded to treatment allocation, using
patient number as the identifier. The images will also be
used to assess global improvement in disease and the PG
inflammation scale (if possible, depending on the quality
of the images).
Both clinicians and participants know their treatment
allocation and so no special measures are required to
allow for breaking of treatment codes. However, treat-
ment allocation will not be revealed to the recruiting
physician until participants’ details and key stratification
variables have been irrevocably entered by the physician
onto the web-based randomisation site.
Primary outcome
The primary outcome is velocity of healing at 6 weeks.
This will be captured for a single target lesion per
patient and measured using digital photography and
Verge Videometry VEV MD (Vista Medical, Winnipeg,
Canada) computerised planimetry [12]. If multiple lesions
are present, the target lesion should be the lesion that is
most able to be photographed on a single plane (that is,
not around the curvature of a limb). Digital images will
be taken at baseline, 6 weeks and when the ulcer has
healed (maximum 6 months). In addition, maximum
longitudinal length and maximum perpendicular length
will be measured in order to provide some measure of
improvement in case of difficulties with the digital
images, or if the lesion extends around the curvature of
a limb. This will be converted to approximate area by
the formula: length ×width × 0.785, which approximates
to an ellipse for the purpose of randomisation and
analysis.
Velocity of healing at 6 weeks was chosen as the pri-
mary outcome as it is unlikely to be compromised by the
single blind nature of the study, and does not require
lengthy follow-up, thus minimising the possibility of
missing data. Previous work in patients with venous leg
ulcers suggests that velocity of healing is a good surro-
gate for subsequent healing [13].
Secondary outcomes
Secondary outcomes include the following: (1) time to
healing assessed by participants (estimated to the nearest
week) based on the time at which sterile dressings are no
longer required for the wound. Healing is confirmed by
the clinician, and documented using digital photography
at the first opportunity. Time to healing is important
clinically as it will be used to confirm the primary out-
come as a useful surrogate measure. It also gives an indi-
cation of duration of treatment, which therefore provides
information on cumulative drug toxicity. (2) PG specific
global assessment of efficacy (derived from a study by
Foss et al. [14]) as assessed by the clinician and the pa-
tient at 2 weeks, 6 weeks and at 6 months (or healed).
This will also be assessed on the digital images by an in-
dependent assessor. (3) Inflammation assessment scale.
This is a combination scale including erythema, border
elevation and exudate (based on a scale reported by Foss
et al. [14]). The inflammation assessment scale is
recorded by the clinician and the participant at baseline,
2 weeks, 6 weeks and when the ulcer has healed (max-
imum 6 months). This will also be assessed on the digital
images by an independent assessor. (4) Self-reported
pain. Each day for the first 6 weeks of the trial partici-
pants report the severity of the pain in a study diary
(none, mild, moderate, severe or extreme), and whether
or not painkillers were taken. (5) Health-related quality
of life assessed at baseline, 6 weeks and 6 months (or
healed), using validated questionnaires: Dermatology Life
Quality Index [15] and the EQ-5day [16]. (6) Time to re-
currence assessed at the end of the trial. A recurrence is
defined as the occurrence of a further episode of PG (at
any site) that appears after the target lesion has been
confirmed as being healed by a physician (or nurse).
Self-reported healing that has not been confirmed by a
medical professional, and which subsequently recurs, will
not be classed as a recurrence and handled as a continu-
ation of the initial episode. (7) Number of treatment fail-
ures. Treatment failures are defined as being participants
who withdraw (or are withdrawn) from their randomized
treatment because of treatment intolerance or worsening
of the PG, or those who continue to have any unhealed
ulcers after 6 months of follow-up. (8) Adverse reactions
to study medications. Adverse events that are classed as
possibly, probably or definitely relating to the study
medication. (9) Cost effectiveness of the compared
treatments.
For participants in the observational study, only effi-
cacy outcomes are being collected (no safety or cost-
effectiveness outcomes will be reported).
Sample size
A total of 140 patients (randomised 1:1 to prednisolone
or ciclosporin) will give the study at least 80% power at a
5% level of significance using a two-sided two-sample
t test to detect a difference in means of 0.5 SDs of the
primary outcome of velocity of healing at 6 weeks. The
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velocity of healing at 6 weeks is defined as the percent-
age change in surface area (measured by planimetry
using digital photographs) over baseline of the target le-
sion. This sample size allows for an approximate 10% loss
to follow-up at 6 weeks. These calculations were per-
formed using Nquery 6.0.2 on Windows XP (Microsoft,
Redmond, WA, USA).
Statistical analysis
The primary analysis will be according to the intention
to treat principle, and will adjust for known prognostic
baseline covariates. There are no formal planned interim
analyses, but progress reports on all data issues are pre-
sented to a Data Monitoring Committee (DMC).
The primary outcome is to be assessed at 6 weeks,
which reduces the likelihood of having missing data for
this outcome. If digital images are not available for any
participants, then the physical length and width mea-
surements recorded by the clinician will be used in place
of the computer generated planimetry measurements. If
neither a digital image, nor physical measurements are
available at 6 weeks, multiple imputation will be used
using the assumption that the data are missing at
random.
All primary outcome data will be double data entered
and 10% of other data will be entered twice and checked
for errors.
Categorical variables will be summarised with the
number and proportion of participants falling in each
category. Continuous variables will be summarised using
the number available, number missing, mean and stand-
ard deviation (SD), or median, 25th and 75th quartiles,
and minimum and maximum values as appropriate.
Differences between treatment groups for the primary
and secondary outcomes will be assessed using Student’s
t test. Linear regression models, adjusting for baseline
covariates, will be used to compare the treatment groups
at 6 weeks for the primary outcome, and any other con-
tinuous secondary outcomes that fit the assumptions.
Cox regression models, adjusting for baseline covariates,
will be used to compare the treatment groups in the ana-
lysis of the time to healing of the target lesion and the
time to recurrence. Proportional odds models, adjusting
for baseline covariates, will be used to analyse the cat-
egorical secondary outcomes, including global assess-
ment of improvement and the inflammation assessment
scale. The self-reported pain and the EQ-5D score will
be summarised by the area under the curve (AUC), using
Generalized linear models with the appropriate distribu-
tion. Patients are required to have the data recorded at
the initial timepoint, and at the 6 week timepoint (for
the 6 week analyses) or the final visit (for the final visit
analyses), so only patients with at least the first observa-
tion and the last observation for the self-reported pain
data, or those with both timepoints for the EQ-5D data,
will be analysed in the first instance. Sensitivity analyses
will be carried out for the self-reported pain outcome
using the ‘last value carried forward’ method for patients
who have missing interim data.
Cost effectiveness
Costs of the compared treatments will be assessed from
the perspective of the health service, using resources
such as inpatient stays, outpatient attendances, primary
care appointments (at surgery), home visits by GP, dis-
trict nurse visits and PG-related treatment costs. Cost ef-
fectiveness will be presented as the cost per healed ulcer
at 6 months.
Health related quality of life will be estimated from
responses to the Dermatology Life Quality Index. Qual-
ity-adjusted life years will be assessed from responses to
the EQ-5D questionnaire, and the incremental cost per
quality-adjusted life years gained will be presented for
the compared treatments. Health state utilities will be
calculated using UK population tariffs. Estimates of re-
source use (from medical records and patient diaries)
will be combined with unit costs, to derive total costs.
Unit costs will be based on study specific estimates and
data from standard sources. Point estimates of mean in-
cremental costs, QALYs, cost per QALY and cost per
resolved episode at 6 months will be reported.
Study organisation and funding
The study is being coordinated through the UK Derma-
tology Clinical Trials Network [17] and the Nottingham
Clinical Trials Unit at the University of Nottingham. It is
funded by the National Institute for Health Research
(NIHR) as part of an NIHR Programme Grant (RP-PG-
0407-10177), and sponsored by the Nottingham Univer-
sity Hospitals NHS Trust. Further research nurse sup-
port is provided through the NIHR Clinical Research
Networks [18].
The trial is being overseen by a Trial Steering Commit-
tee, which includes an independent chair and three other
independent members (one of whom is a patient with
PG). The DMC meets annually (or more frequently as
required), and oversee all ethical and safety issues in ac-
cordance with current regulations and MRC guidelines
for data monitoring committees. All members are inde-
pendent of the study team, although the Trial Manager
and some other members of the Trial Management
Group (TMG) attend the open sessions in order to in-
form the DMC of trial progress. This committee meet at
least once a year.
Discussion
The STOP GAP trial is a unique study that could not be
achieved without the collaborative efforts of large
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numbers of participating dermatologists, nurses, NHS
Trusts and research networks. Recruitment is taking
place at approximately 50 UK (and Ireland) secondary
care dermatology departments, all of whom are contrib-
uting just 1 or 2 participants per year. Investigators are
contributing on a voluntary basis because they believe
that this is an important clinical question that will help
to inform their clinical practice. Such a recruitment
model means that it is not possible to provide dedicated
STOP GAP research nurses at individual sites, and that
the recruiting dermatologists are sometimes isolated.
However, the development of the National Institute for
Health Research (NIHR) Clinical Research infrastructure
in the England (and CRC Cymru in Wales) means that
support is now available to deliver collaborative trials of
this kind, and many nurses are available within partici-
pating NHS Trusts to assist with patient recruitment and
follow-up.
As a model for conducting trials of rare skin conditions,
the STOP GAP trial is methodologically interesting in
that efforts have been made to include all PG patients
who are willing to take part, by inclusion in either the
RCT or the observational study. This means that the trial
will not only deliver the largest RCT ever to have been
conducted in PG patients, but also the largest prospective
case series of patients treated with topical therapy.
The use of a parallel observational study alongside the
RCT also has advantages for recruitment as it means that
patients with mild disease, who are initially considered to
be ineligible for the main RCT, remain in contact with
the trial team. If topical treatment fails and systemic ther-
apy is indicated, these patients can then be considered for
inclusion in the RCT. This approach is particularly useful
for rare conditions, where few patients are seen at recruit-
ing centres and the evidence-base for treatment is poor
(making a prospective case series more valuable).
Trial status
Recruitment into this trial started in May 2009 and is tak-
ing place in approximately 50 secondary care hospitals in
the UK and Ireland. It is anticipated that recruitment will
be completed by December 2012 at the latest.
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